The global systemic lupus erythematous drugs industry is on a trajectory of significant growth, poised to witness a steady ascent over the forecast period. According to comprehensive projections, the market, valued at US$ 183.3 billion in 2020, is anticipated to surge at a substantial Compound Annual Growth Rate (CAGR) of 5% until 2032, reaching a …